Cerebral Toxoplasmosis and AIDS

With a HIV incidence much higher in the DFA than in European French territory, this disease is a major public health problem in these areas, especially in French Guiana.

Cerebral toxoplasmosis is a priority among the opportunistic infections in AIDS patients from the DFA because of its frequency (French West Indies) and of its lethality (French Guiana).

The diagnosis of cerebral toxoplasmosis may be difficult because based only on presumptive clinical and radiological features. The response to specific antitoxoplasmic therapy confirms a posteriori the diagnosis.

In reference to the data collected by the Biological Resource Centre Toxoplasma, in particular in French Guiana, we think that T. gondii strains reactivating in AIDS patients from DFA are genetically different from those reactivating in AIDS patients from Europe, with an increased capacity for dissemination via peripheral blood in the first ones. This more frequent or more prolonged parasitemia could facilitate the diagnosis of cerebral toxoplasmosis by PCR test from peripheral blood samples in AIDS patients from the French departments of America.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cerebral Toxoplasmosis AIDS Abscess Acquired Immunodeficiency Syndrome Blood-Borne Infections Brain Abscess Brain Diseases Central Nervous System Diseases Central Nervous System Infections Central Nervous System Parasitic Infections Central Nervous System Protozoal Infections Coccidiosis Communicable Diseases Genital Diseases HIV Infections Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections Nervous System Diseases Parasitic Diseases Protozoan Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Suppuration Toxoplasmosis Toxoplasmosis, Cerebral Urogenital Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service des Maladies Infectieuses - CHU de Pointe à Pitre, Pointe à Pitre, Guadeloupe, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult patient (> 18 years)
Patient being informed and accepting to participate in the study with signature of informed consent
HIV positive serology
Clinical and radiological suspicion of cerebral toxoplasmosis justifying the start of specific antitoxoplasmic therapy

Exclusion criteria

Protected patient
Patient uncovered by social insurance
Specific antitoxoplasmic therapy already initiated since 72h or more

Treatment and study plan

Toxoplasma PCR assay

Other

Toxoplasma PCR assay

Secondary outcomes

Isolation, genetic typing and storage of T. gondii strains collected among AIDS patients with cerebral toxoplasmosis from the DFA.

Time frame: 3 years

Sponsors and collaborators

Lead sponsor

University Hospital, Limoges

Other

Registry information

Official study title

Cerebral Toxoplasmosis and AIDS in the French Departments of America (DFA). Diagnostic Contribution of a PCR Assay and Genetic Diversity of Toxoplasma Gondii.

Acronym: TOXODFA

Important dates

Study start: 2009
Primary completion: 2012
Study completion: 2013
First posted: Dec 5, 2008
Registry last updated: Jul 5, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed